J. Virol., Sep 1996, 5930-5934, Vol 70, No. 9
Copyright © 1996, American Society for Microbiology

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

PR Harrigan, I Kinghorn, S Bloor, SD Kemp, I Najera, A Kohli and BA Larder
Glaxo Wellcome Research and Development, Stevenage, United Kingdom.

Amino acid variation at reverse transcriptase (RT) codon 210 (generally Leu-210 to Trp [L210W], TTG-->TGG) is occasionally detected after the initiation of azidothymidine (AZT) therapy. The impact of this variation on AZT resistance and viral replication was addressed by four different approaches. The frequency and genetic background of the L210W mutation in vivo were assessed by analyzing sera of AZT-naive and AZT- experienced patients by RT-PCR and DNA sequencing. The degree of AZT resistance (50% infective concentration [IC50]) of recombinant viruses constructed by using the RT of 21 clinical isolates was stratified by the presence or absence of the 210 mutation. The AZT IC50S of a panel of mutant viruses (with or without W-210) constructed by site-directed mutagenesis in an HXB2 background were assayed by using a HeLa CD4 plaque reduction assay. Finally, the effect of the 210 mutation on viral replication was assessed by replication competition of an AZT- resistant virus, RTMN (L-41/Y-215), and RTMN with the W-210 mutation in the presence and in the absence of AZT. In AZT-naive patients, tryptophan at RT residue 210 was rare. After AZT exposure, W-210 appeared in a minority of those patients, most commonly in association with L-41 and Y-215. The presence of W-210 increased the AZTIC50 by two- to fourfold, as determined by both the recombinant virus assay and site- directed mutagenesis. A significant replication advantage in favor of the wild-type L-210 over W-210 was observed, although the selection against the 210 mutant was two- to threefold lower when the viruses were grown in the presence of 5 microM AZT. In summary, the L210W mutation appears to be of marginal significance, conferring approximately two- to fourfold-reduced sensitivity to AZT compared with similar AZT-resistant genomes with L-210. The selection pressure against W-210 may account for the modest proportion of patients in which W-210 appears in vivo.

This article has been cited by other articles:

• Hu, Z., Giguel, F., Hatano, H., Reid, P., Lu, J., Kuritzkes, D. R. (2006). Fitness Comparison of Thymidine Analog Resistance Pathways in Human Immunodeficiency Virus Type 1. J. Virol. 80: 7020-7027 [Abstract] [Full Text]  
• Miranda, L. R., Gotte, M., Kuritzkes, D. R. (2005). The L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Counteracts Enhanced Excision of Zidovudine Monophosphate Associated with Thymidine Analog Resistance Mutations. Antimicrob. Agents Chemother. 49: 2648-2656 [Abstract] [Full Text]  
• Marcelin, A.-G., Flandre, P., Pavie, J., Schmidely, N., Wirden, M., Lada, O., Chiche, D., Molina, J.-M., Calvez, V., the AI454-176 Jaguar Study Team, (2005). Clinically Relevant Genotype Interpretation of Resistance to Didanosine. Antimicrob. Agents Chemother. 49: 1739-1744 [Abstract] [Full Text]  
• Bouchonnet, F., Dam, E., Mammano, F., de Soultrait, V., Hennere, G., Benech, H., Clavel, F., Hance, A. J. (2005). Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues. J. Virol. 79: 812-822 [Abstract] [Full Text]  
• Nurpeisov, V., Hurwitz, S. J., Sharma, P. L. (2003). Fluorescent Dye Terminator Sequencing Methods for Quantitative Determination of Replication Fitness of Human Immunodeficiency Virus Type 1 Containing the Codon 74 and 184 Mutations in Reverse Transcriptase. J. Clin. Microbiol. 41: 3306-3311 [Abstract] [Full Text]  
• Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
• Cho, Y. K., Sung, H., Ahn, S. H., Bae, I. G., Woo, J. H., Won, Y. H., Kim, D. G., Kang, M. W. (2002). Frequency of Mutations Conferring Resistance to Nucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Patients in Korea. J. Clin. Microbiol. 40: 1319-1325 [Abstract] [Full Text]  
• Brenner, B. G., Routy, J.-P., Petrella, M., Moisi, D., Oliveira, M., Detorio, M., Spira, B., Essabag, V., Conway, B., Lalonde, R., Sekaly, R.-P., Wainberg, M. A. (2002). Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection. J. Virol. 76: 1753-1761 [Abstract] [Full Text]  
• Iglesias-Ussel, M. D., Casado, C., Yuste, E., Olivares, I., Lopez-Galindez, C. (2002). In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J. Gen. Virol. 83: 93-101 [Abstract] [Full Text]  
• Lennerstrand, J., Hertogs, K., Stammers, D. K., Larder, B. A. (2001). Correlation between Viral Resistance to Zidovudine and Resistance at the Reverse Transcriptase Level for a Panel of Human Immunodeficiency Virus Type 1 Mutants. J. Virol. 75: 7202-7205 [Abstract] [Full Text]  
• Lennerstrand, J., Stammers, D. K., Larder, B. A. (2001). Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine. Antimicrob. Agents Chemother. 45: 2144-2146 [Abstract] [Full Text]  
• Sato, H., Tomita, Y., Ebisawa, K., Hachiya, A., Shibamura, K., Shiino, T., Yang, R., Tatsumi, M., Gushi, K., Umeyama, H., Oka, S., Takebe, Y., Nagai, Y. (2001). Augmentation of Human Immunodeficiency Virus Type 1 Subtype E (CRF01_AE) Multiple-Drug Resistance by Insertion of a Foreign 11-Amino-Acid Fragment into the Reverse Transcriptase. J. Virol. 75: 5604-5613 [Abstract] [Full Text]  
• Imamichi, T., Berg, S. C., Imamichi, H., Lopez, J. C., Metcalf, J. A., Falloon, J., Lane, H. C. (2000). Relative Replication Fitness of a High-Level 3'-Azido-3'-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thrright-arrowGly) at Codon 69. J. Virol. 74: 10958-10964 [Abstract] [Full Text]  
• Sato, H., Tomita, Y., Shibamura, K., Shiino, T., Miyakuni, T., Takebe, Y. (2000). Convergent Evolution of Reverse Transcriptase (RT) Genes of Human Immunodeficiency Virus Type 1 Subtypes E and B following Nucleoside Analogue RT Inhibitor Therapies. J. Virol. 74: 5357-5362 [Abstract] [Full Text]  
• Richard, N., Salomon, H., Rando, R., Mansour, T., Bowlin, T. L., Wainberg, M. A. (2000). Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants Resistant to the (+) and (-) Enantiomers of 2'-Deoxy-3'-Oxa-4'-Thio-5-Fluorocytidine. Antimicrob. Agents Chemother. 44: 1127-1131 [Abstract] [Full Text]  
• Arion, D., Sluis-Cremer, N., Parniak, M. A. (2000). Mechanism by Which Phosphonoformic Acid Resistance Mutations Restore 3'-Azido-3'-deoxythymidine (AZT) Sensitivity to AZT-resistant HIV-1 Reverse Transcriptase. J. Biol. Chem. 275: 9251-9255 [Abstract] [Full Text]  
• Hertogs, K., Bloor, S., De Vroey, V., van den Eynde, C., Dehertogh, P., van Cauwenberge, A., Stürmer, M., Alcorn, T., Wegner, S., van Houtte, M., Miller, V., Larder, B. A. (2000). A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V. Antimicrob. Agents Chemother. 44: 568-573 [Abstract] [Full Text]  
• Imamichi, T., Sinha, T., Imamichi, H., Zhang, Y.-M., Metcalf, J. A., Falloon, J., Lane, H. C. (2000). High-Level Resistance to 3'-Azido-3'-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1. J. Virol. 74: 1023-1028 [Abstract] [Full Text]  
• Canard, B., Chowdhury, K., Sarfati, R., Doublie, S., Richardson, C. C. (1999). The Motif D Loop of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Is Critical for Nucleoside 5'-Triphosphate Selectivity. J. Biol. Chem. 274: 35768-35776 [Abstract] [Full Text]  
• Larder, B. A., Bloor, S., Kemp, S. D., Hertogs, K., Desmet, R. L., Miller, V., Sturmer, M., Staszewski, S., Ren, J., Stammers, D. K., Stuart, D. I., Pauwels, R. (1999). A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance. Antimicrob. Agents Chemother. 43: 1961-1967 [Abstract] [Full Text]  
• Kosalaraksa, P., Kavlick, M. F., Maroun, V., Le, R., Mitsuya, H. (1999). Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay. J. Virol. 73: 5356-5363 [Abstract] [Full Text]  
• Esté, J. A., Cabrera, C., Blanco, J., Gutierrez, A., Bridger, G., Henson, G., Clotet, B., Schols, D., De Clercq, E. (1999). Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4. J. Virol. 73: 5577-5585 [Abstract] [Full Text]  
• Martinez-Picado, J., Savara, A. V., Sutton, L., D'Aquila, R. T. (1999). Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1. J. Virol. 73: 3744-3752 [Abstract] [Full Text]  
• Tachedjian, G., French, M., Mills, J. (1998). Coresistance to Zidovudine and Foscarnet Is Associated with Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 42: 3038-3043 [Abstract] [Full Text]  
• Arts, E. J., Quinones-Mateu, M. E., Albright, J. L., Marois, J.-P., Hough, C., Gu, Z., Wainberg, M. A. (1998). 3'-Azido-3'-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants. J. Virol. 72: 4858-4865 [Abstract] [Full Text]  
• Harrigan, P. R., Bloor, S., Larder, B. A. (1998). Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro. J. Virol. 72: 3773-3778 [Abstract] [Full Text]